Answers are grounded in this paper and cite their sources.
Formulation of silk fibroin-coated resveratrol nanoparticles improved wound closure in diabetic models, suggesting significant therapeutic potential.
Diabetic wounds remain a major clinical challenge due to delayed healing, persistent inflammation, and limited efficacy of existing therapies. Resveratrol possesses antioxidant, anti-inflammatory, and antibacterial properties but is restricted by poor solubility and rapid degradation. This study developed silk fibroin-coated resveratrol solid lipid nanoparticles (SF-RSLNs) to enhance resveratrol stability, provide controlled release, and improve therapeutic performance in diabetic wound healing. SF-RSLNs were fabricated using a microemulsion technique and optimized through a Box–Behnken design. The optimized nanoparticles exhibited a mean particle size of 222.1 nm, zeta potential of − 32 mV, entrapment efficiency of 85.7%, and drug loading of 10.2%. Characterization was performed using FTIR, SEM, and DLS analyses. In-vitro assessments included cytotoxicity (MTT), antioxidant activity (DPPH and ROS scavenging), antibacterial activity, scratch-wound healing, anti-inflammatory assays, and hemocompatibility evaluation. SF-RSLNs demonstrated sustained drug release ( ∼ 75% over 48 h), enhanced antioxidant activity (85% DPPH scavenging at 40 µg/mL), and significant wound closure (90% at 48 h). Antibacterial activity was improved, with inhibition zones of 18 mm against Staphylococcus aureus and 20 mm against Escherichia coli . SF-RSLNs also reduced TNF-α levels by 65% and increased IL-10 levels by 50%, while exhibiting excellent hemocompatibility. These findings indicate that SF-RSLNs serve as a multifunctional nanocarrier capable of enhancing resveratrol delivery and accelerating diabetic wound repair.
No takes yet. Share an insight, caveat, or question.
Bogadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: